AAP
CGON icon

Arax Advisory Partners’s CG Oncology CGON Stock Holding History

Arax Advisory Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.4K Buy
330
+292
+768% +$19.1K ﹤0.01% 3849
2026
Q1 		$2.57K Sell
38
-3
-7% -$170 ﹤0.01% 3035
2025
Q4 		$1.7K Sell
41
-562
-93% -$23.3K ﹤0.01% 3315
2025
Q3 		$24.3K Buy
603
+567
+1,575% +$16.5K ﹤0.01% 2179
2025
Q2 		$936 Buy
36
+24
+200% +$578 ﹤0.01% 2797
2025
Q1 		$294 Sell
12
-27
-69% -$760 ﹤0.01% 2580
2024
Q4 		$1.12K Buy
+39
New +$1.33K ﹤0.01% 2147

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arax Advisory Partners's CGON Position: Q2 2026 in Review

Arax Advisory Partners increased its CG Oncology (CGON) stake by 768% in Q2 2026, buying an estimated $19.1K and bringing the position to 330 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3849.

Arax Advisory Partners first reported a position in CGON in Q4 2024 and has held it in 7 quarters since. The position peaked at $24.3K in Q3 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Arax Advisory Partners held 330 shares of CG Oncology worth $23.4K as of Q2 2026.
  • Arax Advisory Partners bought 292 CG Oncology shares in Q2 2026, an estimated $19.1K.
  • CG Oncology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3849 holding.
  • Arax Advisory Partners first reported a position in CG Oncology in Q4 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's CG Oncology position peaked at $24.3K in Q3 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.